Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review
Standard
Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review. / Käsmann, Lukas; Niyazi, Maximilian; Blanck, Oliver; Baues, Christian; Baumann, René; Dobiasch, Sophie; Eze, Chukwuka; Fleischmann, Daniel; Gauer, Tobias; Giordano, Frank A; Goy, Yvonne; Hausmann, Jan; Henkenberens, Christoph; Kaul, David; Klook, Lisa; Krug, David; Mäurer, Matthias; Panje, Cédric M; Rosenbrock, Johannes; Sautter, Lisa; Schmitt, Daniela; Süß, Christoph; Thieme, Alexander H; Trommer-Nestler, Maike; Ziegler, Sonia; Ebert, Nadja; Medenwald, Daniel; Ostheimer, Christian; Young DEGRO Trial Group.
in: STRAHLENTHER ONKOL, Jahrgang 194, Nr. 2, 02.2018, S. 79-90.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review
AU - Käsmann, Lukas
AU - Niyazi, Maximilian
AU - Blanck, Oliver
AU - Baues, Christian
AU - Baumann, René
AU - Dobiasch, Sophie
AU - Eze, Chukwuka
AU - Fleischmann, Daniel
AU - Gauer, Tobias
AU - Giordano, Frank A
AU - Goy, Yvonne
AU - Hausmann, Jan
AU - Henkenberens, Christoph
AU - Kaul, David
AU - Klook, Lisa
AU - Krug, David
AU - Mäurer, Matthias
AU - Panje, Cédric M
AU - Rosenbrock, Johannes
AU - Sautter, Lisa
AU - Schmitt, Daniela
AU - Süß, Christoph
AU - Thieme, Alexander H
AU - Trommer-Nestler, Maike
AU - Ziegler, Sonia
AU - Ebert, Nadja
AU - Medenwald, Daniel
AU - Ostheimer, Christian
AU - Young DEGRO Group
PY - 2018/2
Y1 - 2018/2
N2 - PURPOSE: Lung cancer remains the leading cause of cancer-related mortality worldwide. Stage III non-small cell lung cancer (NSCLC) includes heterogeneous presentation of the disease including lymph node involvement and large tumour volumes with infiltration of the mediastinum, heart or spine. In the treatment of stage III NSCLC an interdisciplinary approach including radiotherapy is considered standard of care with acceptable toxicity and improved clinical outcome concerning local control. Furthermore, gross tumour volume (GTV) changes during definitive radiotherapy would allow for adaptive replanning which offers normal tissue sparing and dose escalation.METHODS: A literature review was conducted to describe the predictive value of GTV changes during definitive radiotherapy especially focussing on overall survival. The literature search was conducted in a two-step review process using PubMed®/Medline® with the key words "stage III non-small cell lung cancer" and "radiotherapy" and "tumour volume" and "prognostic factors".RESULTS: After final consideration 17, 14 and 9 studies with a total of 2516, 784 and 639 patients on predictive impact of GTV, GTV changes and its impact on overall survival, respectively, for definitive radiotherapy for stage III NSCLC were included in this review. Initial GTV is an important prognostic factor for overall survival in several studies, but the time of evaluation and the value of histology need to be further investigated. GTV changes during RT differ widely, optimal timing for re-evaluation of GTV and their predictive value for prognosis needs to be clarified. The prognostic value of GTV changes is unclear due to varying study qualities, re-evaluation time and conflicting results.CONCLUSION: The main findings were that the clinical impact of GTV changes during definitive radiotherapy is still unclear due to heterogeneous study designs with varying quality. Several potential confounding variables were found and need to be considered for future studies to evaluate GTV changes during definitive radiotherapy with respect to treatment outcome.
AB - PURPOSE: Lung cancer remains the leading cause of cancer-related mortality worldwide. Stage III non-small cell lung cancer (NSCLC) includes heterogeneous presentation of the disease including lymph node involvement and large tumour volumes with infiltration of the mediastinum, heart or spine. In the treatment of stage III NSCLC an interdisciplinary approach including radiotherapy is considered standard of care with acceptable toxicity and improved clinical outcome concerning local control. Furthermore, gross tumour volume (GTV) changes during definitive radiotherapy would allow for adaptive replanning which offers normal tissue sparing and dose escalation.METHODS: A literature review was conducted to describe the predictive value of GTV changes during definitive radiotherapy especially focussing on overall survival. The literature search was conducted in a two-step review process using PubMed®/Medline® with the key words "stage III non-small cell lung cancer" and "radiotherapy" and "tumour volume" and "prognostic factors".RESULTS: After final consideration 17, 14 and 9 studies with a total of 2516, 784 and 639 patients on predictive impact of GTV, GTV changes and its impact on overall survival, respectively, for definitive radiotherapy for stage III NSCLC were included in this review. Initial GTV is an important prognostic factor for overall survival in several studies, but the time of evaluation and the value of histology need to be further investigated. GTV changes during RT differ widely, optimal timing for re-evaluation of GTV and their predictive value for prognosis needs to be clarified. The prognostic value of GTV changes is unclear due to varying study qualities, re-evaluation time and conflicting results.CONCLUSION: The main findings were that the clinical impact of GTV changes during definitive radiotherapy is still unclear due to heterogeneous study designs with varying quality. Several potential confounding variables were found and need to be considered for future studies to evaluate GTV changes during definitive radiotherapy with respect to treatment outcome.
KW - Journal Article
U2 - 10.1007/s00066-017-1221-y
DO - 10.1007/s00066-017-1221-y
M3 - SCORING: Review article
C2 - 29030654
VL - 194
SP - 79
EP - 90
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 2
ER -